Federated Hermes
CTMX icon

Federated Hermes’s CytomX Therapeutics CTMX Stock Holding History

Federated Hermes’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-398
Closed -$903 – 2142
2025
Q2 		$903 Buy
+398
New +$642 ﹤0.01% 2008
2024
Q4 		– Sell
-117
Closed -$138 – 2100
2024
Q3 		$138 Hold
117
– – ﹤0.01% 2019
2024
Q2 		$143 Sell
117
-4,271
-97% -$8.5K ﹤0.01% 1990
2024
Q1 		$9.57K Buy
4,388
+903
+26% +$1.67K ﹤0.01% 1780
2023
Q4 		$5.4K Buy
3,485
+2,070
+146% +$2.72K ﹤0.01% 1843
2023
Q3 		$1.82K Hold
1,415
– – ﹤0.01% 1975
2023
Q2 		$2.43K Hold
1,415
– – ﹤0.01% 1983
2023
Q1 		$2.14K Sell
1,415
-2,127
-60% -$4.81K ﹤0.01% 1999
2022
Q4 		$5.67K Sell
3,542
-715
-17% -$1.06K ﹤0.01% 1916
2022
Q3 		$6K Buy
4,257
+424
+11% +$652 ﹤0.01% 1873
2022
Q2 		$7K Buy
3,833
+3,752
+4,632% +$7.18K ﹤0.01% 1858
2022
Q1 		$1K Sell
81
-961,393
-100% -$3.69M ﹤0.01% 2076
2021
Q4 		$4.16M Sell
961,474
-123
-0% -$721 0.01% 865
2021
Q3 		$4.89M Buy
961,597
+29,590
+3% +$158K 0.01% 830
2021
Q2 		$5.9M Buy
932,007
+338,586
+57% +$2.64M 0.01% 796
2021
Q1 		$4.59M Buy
593,421
+230,763
+64% +$1.83M 0.01% 881
2020
Q4 		$2.38M Buy
362,658
+344,186
+1,863% +$2.46M ﹤0.01% 1000
2020
Q3 		$123K Buy
18,472
+11,653
+171% +$86.4K ﹤0.01% 1710
2020
Q2 		$57K Buy
+6,819
New +$63.3K ﹤0.01% 1765
2019
Q4 		– Sell
-6,970
Closed -$51K – 2225
2019
Q3 		$51K Buy
+6,970
New +$68.8K ﹤0.01% 1723
2018
Q2 		– Sell
-125,932
Closed -$3.58M – 2211
2018
Q1 		$3.58M Buy
125,932
+56,582
+82% +$1.61M 0.01% 741
2017
Q4 		$1.46M Buy
+69,350
New +$1.44M ﹤0.01% 1068

Other funds holding CTMX

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Federated Hermes's CTMX Position: Q3 2025 in Review

Federated Hermes sold out of CytomX Therapeutics (CTMX) in Q3 2025, closing a stake of 398 shares — an estimated $903 sold.

Federated Hermes first reported a position in CTMX in Q4 2017 and held it in 22 quarters. The position peaked at $5.9M in Q2 2021. 103 funds tracked by Wall St. Rank hold CTMX as of Q3 2025.

  • Federated Hermes reported no remaining CytomX Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Federated Hermes sold 398 CytomX Therapeutics shares in Q3 2025, an estimated $903.
  • Federated Hermes first reported a position in CytomX Therapeutics in Q4 2017 and held it in 22 quarters.
  • Federated Hermes's CytomX Therapeutics position peaked at $5.9M in Q2 2021.
  • 103 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.